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INTRODUCTION 
 
Acute angle closure glaucoma has always been a threatening and 
dangerous disease and one of the leading cause of blindness in Human 
society. Nearly all cases of blindness from glaucoma is preventable if 
disease is detected early and proper treatment is implemented. 
In 1956 Gerd Meyer Schwickerath demonstrated the feasibility of 
creating an Iridectomy with Xenon light energy. 
The LASER , a technologic improvement over Xenon light source 
has allowed iridectomies to be performed more safely than by standard 
methods because of many reasons as eye need not be opened, procedure 
requires only topical anaesthesia, procedure is less expensive and requires 
only shorter post operative recovery. 
Nd-YAG laser iridotomy has become the currently preferred 
method  for relieving the pupillary block. This study will attempt to look 
at the efficacy of Nd-YAG laser in creating iridotomy in cases of primary 
angle closure glaucoma. 
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AIM OF THE STUDY 
This study is intended to evaluate the efficacy of Nd-YAG 
laser iridotomy in acute angle closure glaucoma with a follow up of 
12 weeks. 
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REVIEW OF LITERATURE 
The first attempt at creating an iridotomy with xenon light energy 
was done 50 years ago by Gerd Meyer Schwickerath,(1) a young 
Hamburg Ophthalmologist. 
Perkins E.S in 1971 had suggested the use of laser iridotomy for 
secondary glaucoma(2). After about two years Perkins E.S and Brown 
N.A.P had reported the successful iridotomy with ruby laser(1973)(3). 
In 1975 Abraham R.K and Miller G.L published the results of two 
years study of Argon laser iridotomy as an outpatient procedure, more 
safe and requiring only topical anaesthesia.(4) 
Currently two types of laser are commonly used for iridotomies , 
the Nd-YAG  and the Argon (5). Many clinical studies were published 
comparing Q- switched Neodymium- YAG with Argon for peripheral 
iridotomy ( MC Alister J A , Schwartz L.W, Moster.M). 
Pollack I.P in 1979 and Quigley H.A in 1981 had published the 
results of a long term study of YAG laser iridotomy and had suggested 
that Nd- YAG laser is preferable over Argon because it is easy to use 
,more likely to penetrate the iris and less chance for these iridectomies to 
close over time.(6,7). 
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In 1984 Schrems.W et al indicated that the disturbance of the blood 
aqueous barrier with Nd-YAG laser is not essentially different from that 
of Argon laser, although tissue damage may be more pronounced.(7). 
Klapper R.M in 1984 studied 20 patients who underwent Q 
switched Nd-YAG iridotomy for angle closure glaucoma . Of this 11 eyes 
were previous argon laser failures. Penetration was achieved in each case 
with several shots in one session. Complications were minor and 
transient.(8) 
Robin A.L , Pollack I.P reported in their clinical study of 40 eyes 
of 20 patients that immediate post operative IOP  was greater than 10 mm 
of Hg in 35% cases using Argon and 30% in YAG laser treated eyes. 
Other complications reported were haemorrhage, lens damage , focal 
corneal opacities and endothelial damage.(9) 
In 1984 Buchner.M. Gloor and Robert.Y conducted a long term 
study comprising of 124 eyes and brought out the conclusions that       
Nd-YAG laser iridotomy should be the procedure of first choice in 
narrow angle conditions since fistulizing procedures involve risk of 
malignant glaucoma. It helps to alleviate the angle closure component, to 
diagnose its contribution to peak IOP and to facilitate an argon laser 
trabeculoplasty when needed.(10) 
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Yassur .Y, Melamed.S et al had recorded that  Argon laser 
iridotomy is the procedure of choice for eyes with acute angle closure 
glaucoma and for preventive iridotomy in the fellow eye.(11) 
Cashwell.L.F in his series of 112 eyes with 6 months follow up 
observed that when cornea is clear laser iridotomy is a better alternative 
to surgical iridectomy and can be used in out patients without the risk of 
intra ocular surgery. This alternative is especially beneficial to patients 
with combined mechanism glaucoma and to patients in whom surgery is 
contraindicated. (12) 
In the same year Yamamoto.T, Shirato.S, Kitazava.Y performed 
Argon laser iridotomy in a total of 140 eyes of 140 patients with primary 
angle closure glaucoma. The IOP was controlled at below 20 mm of Hg 
in 29%  without medication, 52% with reduced or the same medication as 
the pre operative treatment and in 13% with increased medication. In 
6%IOP could not be controlled. (13) 
Rivera  A.H, Browns. R H and Anderson D.R in 1985 believed that 
increased use of an easy, low risk procedure represents improvemenrs in 
the quality of care.(14) 
In 1986 Schrems. W et al conducted a prospective clinical trial 
comprising of 41 eyes with narrow angle glaucoma and a control group of 
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10 normotensive  eyes.The patency of  YAG laser iridotomy was checked 
after application of a rapidly acting parasympatholytic drug like 
tropicamide. Tropicamide mydriasis had no effect on IOP either in 
patients group or in the control group.(15) 
Naveh. N , Zborowsky-M Gutman.L, Blumenthal.M conducted 
preliminary clinical study to evaluate the efficacy and immediate 
complications of Q switched Nd-YAG laser iridotomy in the treatment of 
acute and chronic angle closure. 90% cases required a single lasing 
session for patency and 10% required two sessions. Both these incidences 
are remarkably lower than that of argon laser iridotomy. Transitory 
closure of a prior patent iridotomy during the first hour after lasing was 
observed in 6.7% eyes. Patency was again noted up to three weeks and 
remained unchanged. 
Immediate post operative complications included a marked in 
crease in IOP (42%), minimal transitory bleeding, transitory localized 
corneal odema at the lasing site .persistent iridocorneal adhesion at the 
lasing site was noted in three eyes, localized Lenticular opacities of non 
progressive type in one eye.(16) 
Robin A.L Arkell.S. et al had done a field trial with a portable laser 
system. Prophylactic iridotomies were created with small portable, 
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battery operated, Q switched Nd-YAG laser with a slit lamp delivery 
system, in 44 Eskimos eyes with occludable angles.(17) 
Mentges W.M, Heider.W and Ohrloff. C suggested that 
prophylactic Nd-YAG iridotomy is avaluable therapeutic procedure for 
the prevention of acute glaucoma in the fellow eye of one already found 
to be affected by glaucoma.(18) 
In 1992 HO.T and Fan.R reported clinical study to evaluate the use 
of the Argon and Nd-YAG laser in sequential combination for iridotomy. 
Sequential argon YAG laser iridotomy combines most advantages of both 
laser types while avoiding some of their  disadvantages.(19) 
In the same year late histopathological findings of Nd-YAG laser 
iridotomies in humans by Tetsumo.K et al suggested that in human iris 
wound healing after Nd-YAG laser  iridotomy occurs without induction 
of fibrous scar or proliferationof iris pigments in the epithelium. This 
indicates that there is no tendency towards late closure of the iridotomy 
sites.(20) 
Observations by Li.J.z in 56 eyes of PACG( published in 1991) is 
that success rate of 100% with lowering of IOP pf 2.3 mm of Hg, along 
with diminished use of hypotensive drugs.(21) 
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Murphy P.H and Trope G.E reported 13 cases of monocular 
blurring or a bluish or coloured line after laser procedure.(22) 
Fernandez and Rechemonde J.L reported  iatrogenic lens  
complications like lens rupture , lens opacities and lens dislocation after a 
Nd-YAG laser attempt. They have also suggested that a proper patient 
selection, good techniques with cautious use of laser energy and 
meticulous attention to details should prevent this complication.(23) 
Malignant glaucoma was reported by Robinson.A et al in 1990.(24) 
 Malignant glaucoma was again observed with acute angle closure 
in 6 eyes  after Nd YAG laser iridotomyby Cashwell and Martin.(25)  
 Corneal endothelial loss was reported by Power. M.J and 
Collins.L.M and they have also observed that area of cell loss was 
reduced by approximately 50% when Abraham goniolens was used.(26) 
Smith .T preferred using Argon laser pretreatment in the Nd YAG 
iridotomy as it was proved to significantly reduce the incidence of 
haemorrhage during Nd-YAG iridotomy.(27) 
 A study by Fleck B W in 4 cases of acute angle closure glaucoma 
has pointed out that an iridotomy should be atleast150-200 microns in 
diameter if acute angle closure glaucoma is to be reliably prevented.(28) 
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Nd: YAG laser iridotomy is effective in widening the drainage 
angle and reducing elevated IOP in east Asian people with primary angle 
closure. This suggests that pupil block is a significant mechanism causing 
closure of the angle in this population. Once glaucomatous optic 
neuropathy associated with synechial angle closure has occurred, 
iridotomy alone is less effective at controlling IOP.(42) 
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ANATOMY OF ANGLE OF ANTERIOR 
CHAMBER 
Development : 
Anterior chamber commences peripherally as a slit in the 
mesoderm between cornea and iris which gradually progresses centrally. 
The appearance of this cleft is probably due to disappearance of 
mesoderm between developing iris and cornea at about 30-40mm stage. 
The anterior chamber is soon seperated from the lens by the 
pupillary membrane. It is always shallow and is still so at birth. 
The region of the future angle is at first filled with loose 
mesodermal tissue which later disappears except for the portion at the 
extreme periphery. 
Angle of the anterior chamber:  
It is the peripheral recess bounded by the posteriorly by root of the 
iris and ciliary body and anteriorly by the corneosclera. The various 
pathways of aqueous from anterior chamber to the venous system include 
the trabecular meshwork, juxtacanalicular tissue, endothelium of the 
schlem’s canal and the collector channels. 
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Trabecular meshwork: 
In the meridional section the trabecular meshwork has a triangular 
shape with its apex at schwalbe’s line and its base at sclera spur. The 
meshwork consists of a stack of flattened, interconnected, perforated 
sheets which run in meridional fashion from peripheral cornea and 
descemets membrane anteriorly to scleral spur posteriorly. Anteriorly 
these sheets are only 2-3 layers thick, but posteriorly 12-20 layers are 
detectable. The inner layer of trabecular meshwork border the anterior 
chamber and are referred to as uveal meshwork. The outer layers are 
separated from endothelial of schlemm’s canal by a thin strip of 
connective tissue called juxta canalicular tissue. The ultra structure of 
trabecular  meshwork consists of  trabecular  beams with a central core of 
collagen types I, III and elastin. The core is surrounded by a cortical zone 
that contains collagen types III, IV, V, laminin, fibronectin, heparin 
sulphate and proteoglycan. The beams are coveredby a continous layer of 
endothelial cells that are joined by gap junctions and tight junctions. The 
endothelial cells have micro filaments including actin. 
Juxta canalicular tissue:   
It is a thin layer of tissue 2 -20 microns thick that separates the 
outer layers of corneoscleral meshwork from the inner wall of schlemm’s 
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canal. The tissue has a ground substance of glycosaminoglycans and 
glyproteins that contain type III collagen, curlycollagen, fibroblasts and 
star shaped cells( juxta canalicular cells). 
Schlemm’s canal: 
  It is an endothelial lined circular channel that runs 
circumferentially around the globe. It has a slit like lumen that is 190-370 
microns in diameter. However in some eyes the lumen is irregular and 
even become a plexiform channel with multiple braches. The outer wall 
of schlemm’s canal has a single layer of endothelium that lacks pores or 
vacuoles. The endothelium linning the inner wall of schlemm’s canal 
consists of a mono layer of spindle cells. 
Collector channels: 
Schelmm’s canal is drained by 20-30 collector channels that in turn 
drain into a complex system of intrascleral, episcleral and subconjunctival 
venous plexus. The collector channels arises from the outer wall of 
schlemm’s canal at irregular intervals of 0.3 to 2.8mm. a few vessels may 
proceed directly from schlemm’s canal to the episcleral and conjunctival 
veins. 
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Scleral spur: 
The scleral spur is a fibrous ring that on meridional section appears 
as a wedge that projects from inner aspect of anterior sclera. The spur is 
attached anteriorly to the trabecular meshwork and posteriorly to the 
sclera and the longitudinal portion of ciliary muscle. When the ciliary 
muscle contracts it pulls the sclera spur posteriorly which increases the 
width of inner trabecular spaces and prevents schlemm’s canal from 
collapsing. The spur consists of collagen types I and III and elastic tissue 
oriented in circular fashion. 
Schwalbe’s line: 
Schwalbe’s line is an irregular elevation, 50-150 microns width 
that runs circumferentially around the globe. This line or zone marks the 
transition from trabecular to endothelium, termination of descemet’s 
membrane, and the insertion of trabecular meshwork into corneal  stroma. 
Schwalbe’s line is composed of collagen and elastic tissue. 
Anatomy of iris: 
The thin circular diaphragm with an average diameter of 12mm and 
thickness 0.5mm, except at collarette, where it is slightly thicker. Root of 
the iris at the middle of the anterior aspect of ciliary body and it is thinner 
peripherally. 
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Iris separates anterior chamber from posterior chamber and is 
bathed in the aqueous fluid on both aspects. The pupil permits flow 
between 2 parts of aqueous cavity of the eyeball. The pupil is a central 
aperture which serves as a path for light to enter the eye. 
Surface of iris has radial ridges in the peripheral part and crypts of 
Fuch’s in the region of circulus minor. At the floor of ridges and the 
crypts the superficial tissue layers of the iris are deficient, a point of 
importance for laser iridotomy. The iris contains pigment (melanin) in 
dark races and surface looks smooth and homogenous. 
The collarette which is about 1.6mm from the pupillary margin 
divides iris surface in 2 parts, pupillary and ciliary zones. 
The layers of iris from before backwards are:- 
1. The anterior limiting membrane: 
A condensation of anterior part of  stroma. The anterior limiting 
membrane is deficient at the crypts and much thinned at the 
contraction furrows. The color of iris depends on the anterior 
limiting membrane. In blue iris, anterior limiting membrane is thin. 
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2. Stroma: 
        consists of loosely arranged collagenous network in which are 
embedded following structures: 
a)   the sphincter pupillae muscle 
b)   blood vessels & nerves of iris 
c)   pigment cells and other cells 
Sphincter pupillae:  
1 mm broad, forming a rim all round the pupillary margin near the 
posterior surface of iris. Derived from ectoderm, when it contracts it 
constricts the pupil. Supplied by oculomotor nerve via short ciliary  
nerves. Each portion of sphincter adheres firmly to surrounding structures 
by vessels and by radial bundles of connective tissue. Hence after an 
iridotomy the portion of sphincter remaining does not contract up and the  
pupil can still react to light. 
Blood vessels forming the bulk of iris run radially. In most part the 
sinuous course allows the free movement of the iris. They straighten out 
when the iris contracts and become wavy , when the iris dilates. There is 
anastomosis of  the vessels at the root – circular anastomosis major and at 
the pupillary margin- circular anastomosis minor (arteriovenous 
anastomosis). 
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Nerves are derived from the long and short ciliary nerves. 
Pigment cells  : they are melanocytes. 
Other cells :   fibroblasts, macrophages and mastocytes. 
3. Posterior membrane- 
also known as anterior epithelium. Sometimes equated with dilator 
pupillae. It has non striated muscle cells, these dilator fibers merge with 
sphincter pupillae close to sphincter. 
4. Posterior Epithelium- 
   This layer is derived from internal layer of optic cup. It has columnar 
epithelium with dark brown pigment cells- round or spindle shaped. After 
lining posterior surface it may curl round at papillary margin giving rise 
to black fringe. The posterior surface of iris is almost touching anterior 
surface of lens at the papillary area. 
Types of Iris: 
Dark iris- 
The dark iris occurs most commonly in black and oriental patients. 
The stromal pigment is dense and the iris relatively thick, which gives it a 
firm, sometimes board like consistency. The dark iris is also referred to as 
hard  iris. The frequency of surface crypts is variable, but even when they 
are present  the underlying stroma may be difficult to penetrate. 
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Medium brown iris – 
Light to medium brown in color and often Containing numerous 
crypts, this is generally the easiest to penetrate. 
Fuzzy brown iris- 
Light to moderate dark brown, this iris has a homogenous surface 
appearance with few or no crypts. The surface pigments of the fuzzy 
brown iris is very soft. Areas of darker, more granular pigment often 
overlie crypts and should be chosen as sites for penetration. If contraction 
burns are used in these irides, one should begin with low power in order 
to avoid bubble formation or  pigment liberation. Beneath the pigmented 
surface layer of melanocytes and fibroblasts, the pigmentation of the 
stroma may be vary from totally lacking to dense and it is important to 
vary the approach and settings accordingly to the situation. 
Blue iris- 
Depending on the degree of stromal  pigmentation, these irides 
range from hazel or bluish brown with numerous crypts( easy to penetrate 
with argon laser) to light grey with no crypts and superficial stroma that 
appears almost structureless ( difficult to penetrate with argon ). The Nd 
YAG laser is particularly useful in very light irides. 
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Soft iris: 
In a soft iris moderate power coagulations create significant 
contraction  of the surrounding stroma towards the site of impact. In such 
cases the iris stroma appears to flow into the site of iridotomy as one 
attempts to penetrate. These irides are usually light brown and often 
require preliminary contraction burns. 
Physiology of aqueous outflow system 
The trabecular meshwork and the outflow channels perform a 
number of important functions. They help in egressing of aqueous humor; 
trabecular endothelial cells phagocytose particulate matter and debris and 
provide structural support to prevent the collapse of schlemm’s canal. 
Routes of Aqueous outflow: 
The two important routes of Aqueous outflow are:- 
1) Trabeculo canalicular outflow 
2) Uveoscleral outflow 
1) Trabeculo-canalicular outflow (Conventional route) 
This accounts for approximately 90% of aqueous outflow. The 
aqueous traverses uveal meshwork, corneoscleral meshwork, 
juxtacanalicular tissue and endothelial linning of canal. From the canal 
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fluid is transferred by 20-30 collector channels to an intrascleral 
venous plexus and anterior ciliary vein. Some of the aqueous is carried 
directly from schlemm’s canal to episcleral plexus by the aqueous 
veins. Trabecular meshwork acts as a one-way valve and it is a crucial 
part of normal aqueous blood barrier. Another important function of 
trabecular meshwork is that the trabecular endothelial cells actively 
phagocytoses foreign material and debris where it acts as 
reticuloendothelial system of anterior segment of eye.  
   Trabecular meshwork directly regulates intraocular pressure or 
tissue distension and then provides feed back to modulate some 
process such as aqueous humor formation, ciliary muscle tone or 
glycosaminoglycan synthesis. 
2) Uveoscleral outflow (also known as uveo vortex/ extracanalicular 
or un conventional route) 
Accounts for 10% of drainage of aqueous . uveoscleral flow seems 
more primitive and resembles a leak more than a well designed fluid 
transport system. The aqueous humor enters the ciliary muscle until it 
reaches supraciliary and supra choroidal spaces. Uveoscleral flow 
increases when intra ocular pressure is raised from atmosphere 
pressure to the level of episcleral venous pressure. An increased IOP 
provide a greater driving force for Uveoscleral flow. 
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PRIMARY ANGLE CLOSURE GLAUCOMA (PACG) 
INTRODUCTION: 
PACG is a condition in which aqueous outflow is obstructed solely 
as a result of closure of the angle by the peripheral iris, occurs in 
anatomically predisposed eyes and is frequently bilateral. Affects 1 in 
1000 over 40 years age. Male : Female ratio 1 : 4. 
Predisposing factors: 
They may be     1)   Anatomical    
                         2)   Physiological 
1) Anatomical: 
     They are a) relatively anterior location of iris lens diaphragm. b) 
shallow anterior chamber c) narrow entrance to the chamber angle. 
Three inter related factors are responsible for these characteristics 
namely axial growth of the lens, small corneal diameter and short axial 
length. 
2) Physiological: 
In predisposed eyes, PACG may occur when the dilator muscle 
contracts, excerting a posterior vector which increases the amount of 
apposition between the iris and anteriorly located lens, this in turn 
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enhances the degree of physiological pupillary block. The 
simultaneous dilation of the pupil renders the peripheral iris more 
flaccid. The relative pupil block causes the pressure in the posterior 
chamber to increase and peripheral iris bows anteriorly (iris bombe). 
Eventually the angle becomes obstructed by the peripheral iris and 
IOP raises. 
Clinically  they can be classified into the following five stages even 
though the condition does not necessarily progress from one to the next 
in an orderly sequence. 
1) Latent  2) Intermittent (sub acute) 3) Acute (congestive & post 
Congestive) 4) Chronic 5) Absolute. 
1) Latent angle closure glaucoma: 
This stage is characterised by a shallow anterior chamber, a convex 
shaped iris diaphragm, close proximity of the iris to the cornea, normal 
IOP, narrow angle capable of closure (Shaffer grade 1-2). Without 
treatment an eye with latent PACG may remain normal, it may develop 
acute angle closure or to chronic angle closure without passing through 
other stages.  
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Treatment: 
Depends on fellow eye. If it has acute or intermittent PACG, 
treatment is by laser iridotomy. Since without treatment the risk of an 
acute attack during next 5 years in 50%. 
2) Intermittent angle closure: 
This occurs when the angle is narrow in only one part.  A rapid partial 
closure and reopening of angle occurs which may be precipitated by 
physiological mydriasis such as watching TV in dark room, physiological 
shallowing of anterior chamber when the patient assumes a prone or a 
semiprone position, or by emotional stress. Without treatment  some eyes 
develop an acute attack  where as others pass straight in to chronic angle 
closure phase. The patients usually presents with transient blurring of 
vision associated with haloes resulting from corneal epithelial oedema. 
There may be some eye ache or frontal headache. The attacks are 
recurrent and usually broken after 1-2 hrs by physiological miosis. 
 
Treatment: 
        Is with intensive miotic therapy using pilocarpine-2% one drop 
every 5 min. the fellow eye should also  be treated prophylactically with 
1% G. pilocarpine four times daily and later with bilateral laser peripheral 
iridotomies.  
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3) Acute congestive angle closure glaucoma: 
This stage is characterized by sudden and severe elevation of IOP as a 
result of total closure of the angle. This stage presents with rapidly   
progressive impairment of vision associated with periocular pain  and 
congestion. Nausea and vomiting may occur in severe cases. On 
examination during acute stage shows a ciliary flush, elevated IOP, 
odematous cornea with epithelial vesicles. Anterior chamber is shallow 
with peripheral irido corneal contact which is best detected by directing a 
narrow slit beam on to the limbus at an angle of 900. The pupil  is 
vertically oval, fixed in semi dilated position, unreactive to both light and 
accommodation. Subsequent examination after corneal oedema has 
cleared shows aqueous flare and cells, dilated and congested blood 
vessels on iris, odematous hyperemic optic disc. 
Initial treatment: 
         This stage is initially treated with systemic medication like 
acetazolamide orally or I.V, hyperosmotic  agents  like mannitol. Topical 
medication with beta blocker twice daily may be helpful in reducing IOP. 
Once the IOP is controlled 2% G pilocarpine is  instilled  twice (15 min 
apart) and then 1% G pilocarpine drops four times daily and then a 
prophylactic laser iridotomy.  
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Subsequent treatment: 
           It is aimed at re establishing the communication between the 
posterior and anterior chamber by making an opening in the iris 
peripheral iridotomy is usually done in cases with  less than 50% angle 
closure by peripheral anterior  synechae. If more than 50% is closed 
filtration procedure is usually required. In  practice, however most eyes 
are treated first by laser iridotomy and filtration surgery is reserved for 
those that fail to respond. 
4) Chronic  angle closure glaucoma: 
        The clinical  features of chronic PACG are those of POAG except 
that gonioscopy shows a variable amount of angle closure. If routine 
gonioscopy is not performed in all cases the diagnosis will be missed. 
The management depends on the mechanism of angle closure is as  
follows. 
a) Group 1:  
          This is characterized by creeping synechial angle closure  which 
starts superiorly and spreads inferiorly. Initially treatment is by laser 
iridotomy to eliminate any pupil block, prevent the development of new 
peripheral anterior synechiae and to make medical control easier. If the 
iridotomy and medical therapy are ineffective, filtration surgery will be 
required. 
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b) Group 2: 
       Occurs as a result of intermittent attacks. These cases will already 
have had a laser iridotomy so that medical therapy should be added as 
and when necessary. 
c) Group3: 
        Is caused by the combination of POAG with narrow angles , 
usually associated with the long term use of miotics. These cases should 
be treated by laser iridotomy to make medical therapy more effective. 
5) Absolute stage  : 
 It is the final phase to which a chronic phase glaucoma may pass on to 
with or without the phase of intermittent subacute attacks. In this stage 
the eye is completely blind, anterior ciliary vessels are dilated and  a 
reddish blue zone surrounds the cornea, cornea is clear, but insensitive 
with or with out vesicles( bullous keratopathy). The  anterior chamber  is 
very shallow, the iris atrophic and may have a broad zone of pigment 
around the pupil. The optic disc is deeply cupped with a very high 
intraocular tensions. The eye is generally painful with temporary 
exacerbations and eventually suffers degenerative changes like ciliary or 
equatorial staphyloma. 
Treatment :  A painful blind eye due to absolute glaucoma can be treated 
with cyclotherapy . 
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LASER IRIDOTOMY IN PACG 
Instrumentation: 
LASER - Light Amplication of Stimulated Emission of Radiation. 
Basic Principles: 
              It was Albert Einstein who speculated that if an atom with an 
excited electron was struck by a photon and the photon has a energy level 
equal to the difference between the electrons higher and lower levels, 
then the incoming  photon could trigger the atom to return to its ground 
state by releasing a photon. This process is called stimulated emission and 
the photon released would have the same wavelength, direction and phase 
as incoming photon. Thus a single photons can produce two identical  
photons and stimulated emission has the potential for producing a chain 
reaction. 
Thus if a system described above is enclosed between two mirrors , 
the photons will bounce back and forth creating multiple stimulated 
emission of light otherwise termed light amplification. The mirrors are set 
to form a cavity which in addition to amplifying the light creates a 
parallel beam and acts as a  resonator to limit the number of wavelengths. 
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Elements of a laser: 
All ophthalmic laser require three basic elements to operate- 
1) There must be an active medium that emits coherent radiation. The 
medium may be gas- argon, krypton 
                                       solid- ruby, Nd- Yag. 
2) Suitable energy source that can pump the atom molecules or ions. 
3) Some form of optical feed back or gain. 
Types  of laser: 
Laser are classified into the following types, solid, Gas, Dye and 
Excimer. 
The laser beam can be delivered as a continous wave or pulsed mode. 
In the latter situation which is more common, the energy is concentrated 
and delivered in a very short period or time which can be accomplished in 
one of the two ways. 
A) Q – Switching :- where light is not allowed to travel back and forth in 
the cavity until maximum population inversion is reached. This is 
achieved by an electric shutter or misalignment of the mirrors. When 
the shutter is opened or the mirrors are aligned stimulated emission and 
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light amplication occur  suddenly and energy is released in a pulse  of a 
few to tens of nano seconds. 
B) In Mode Locking:- the energy released after achieving maximum 
population inversion and different modes of light are synchronized 
creating peaks of energy which are emitted in tens of nano seconds as a 
chain of pulses each of which lasts for a few tenths of pico seconds. 
C) Nd-YAG Laser- This is the most common solid state laser. The active 
element is a triple ionized Neodymium(N+3) that is incorporated in to a 
host material called synthetic Yttrium- Aluminium - Garnet crystal (Y3 
A15 O2). Nd YAG laser rods are available in diameters of  1 to 10 mm 
and lengths  50 to 150 mm. the  Nd YAG is optically pumped by a flash 
lamp which is focused on it  by an elliptically reflecting cavity, the laser 
rod and lamp being at foci. Approximately 1% of the Yttrium ions are 
replaced by the Nd +3 ions during crystal growth and only 2% of the 
electrical power brought in to the flash light is converted in to laser 
energy with the remaining 98% wasted as heat. The Nd YAG emits 
radiation at 1064nm and can be operated in a continous wave or in 
various pulsed modes. 
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PROPERTIES OF LASER ENERGY: 
a) Coherence:- The photons are in phase with each other in line 
and space. 
b) Collimation: Light amplification occurs only for photons that 
are aligned with the mirrors. A nearly parallel beam is produced 
so as to provide a small focal spot when the light is delivered 
through an optical system. 
c) Monochromacy: narrow range of wavelength of the length of 
the laser beam as the photons are emitted due to release of 
energy between two defined levels of atoms. 
d) High intensity: the light amplification of a laser can produce a 
beam with significantly more intensity than that of the sun. 
Laser delivery system: 
Most laser units utilizes a slit lamp biomicroscope in which a 
system of fiber optics and / or mirrors in an articulated arm direct the 
laser beams from the laser tube through the slit lamp into the patient’s 
eye. Various types of contact lenses are used in laser surgery. Some 
contain mirrors to direct the laser beam in to anterior chamber angle, 
while others incorporate convex lenses to concentrate the light energy on 
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the iris. An aiming beam of attenuated laser energy like low power He-Ne 
with a red beam at 632.8 nm coaxial with Nd-YAG pathway allows the 
surgeon to position and focus the laser beam on the target tissue. 
INDICATIONS: 
         Laser iridotomy can be used as an alternative to surgical iridectomy 
in almost any situation in which the iridectomy is a necessary and these 
indications are as follows. 
a) Imperforate surgical iridectomy. 
b) Nanophthalmos 
c) In cases where surgical iridectomy is  not safe. 
d) Cases where surgical iridectomy is refused. 
e) Fellow eye after a complicated surgical iridectomy. 
f) Fellow eye in malignant glaucoma. 
g) Chronic angle closure glaucoma. 
h) Combined mechanism glaucoma. 
i) Pupillary block after cataract operation. 
j) Suspected malignant glaucoma. 
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Energy Setting: 
  Although energy levels vary widely from machine to machine and 
sometimes within the same machine, majority of iridotomies are made 
with settings between 3 and 30 mJ/ shot. Minimum settings for an 
iridotomy in blue iris using Abraham’s lens are approximately 3 to 4 mJ/ 
shot and with 1 to 3 shots / burst. Energy levels from 50% to 100% higher 
are necessary when performing iridotomy on thick brown iris. Energy 
delivery can be increased by using more power/ shot or more shots/ burst. 
Proper focus is absolutely essential. The aiming beam is focused so 
that it is exactly on the anterior surface of the iris. The Nd- YAG laser 
beam is not retro focused so that it will strike in exactly the same position 
as the aiming beam. Power beam and aiming beam should be exactly 
coincidental and it should be checked periodically. 
SITE OF IRIDOTOMY: 
Any quadrant can be used for laser iridotomy although the superior 
nasal quadrant is the most preferred site.  It has the advantages of  
1) Iridotomy is beneath the upper lid. 
2) Laser beams are directed towards nasal periphery of the retina. 
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Iridotomy is usually made in between the middle and outer 1/3 of 
the iris. However if this is not feasible due to peripheral corneal haze or 
proximity of peripheral iris and cornea, a more central location may be 
used as long as it is peripheral to the sphincter muscle. Depending on the 
pigmentation of iris, the iridotomy technique can be suitably tailored for 
medium brown iris, dark brown iris and blue iris. 
The iridotomy should be placed as close to limbus as possible 
without causing endothelial cell burns due to the proximity of the iris to 
the endothelial surface. This is usually three quarters of the way from 
pupil to limbus with an argon laser. The 12’O clock position is usually 
avoided because bubbles created during iridotomy can migrate to this 
area and block visualization. 
To prevent later mono ocular diplopia, the iridotomy should be 
performed within 2 mm of the base of the iris and an area along the 9 ‘O 
clock and 3’O clock involving the palpebral fissure should be avoided. 
Technique: 
An area of thin iris or a large crypt is usually easier to penetrate. In 
lightly pigmented eyes a local area of increased pigmentation such as a 
freckle may improve the absorption of laser energy. In the blue iris the 
radially arranged white collagen strands in the stroma  are very difficult 
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to penetrate with argon laser and it is helpful to select a treatment site 
where two strands are more widely separated. (Hoslun’s HD Miggliazzo 
CV, laser iridotomy technique for blue irises. Ophthalmolo Surgery 
15:488, 1984) 
When compared to either continous wave or pulsed argon lasers the 
Q switched Nd-YAG laser has the advantage of producing a quicker , 
more efficient iridotomy with equal or fewer complications including less 
frequent closure of the iridotomy. 
The extremely high energy levels and short exposure times of 
pulsed Nd-YAG lasers electro mechanically disrupt the tissues, 
independent of pigment absorption and the thermal effect. The technique 
involves perforation of the iris with energy levels in the range of 5 to 
15mJ. Pulsed duration and spot size are fixed and Abraham’s lens can be 
used to focus the beam more precisely. 
Focusing through the Abraham lens on the iris surface the red 
Helium Neon double beam may focus to a single spot and then advancing 
further 0.1mm posterior through the anterior surface into depth of iris 
stroma the single spot again becomes two spots. This indicates focus at a  
slightly deeper iris stroma than the anterior surface. 
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Caution should be used to avoid firing the laser through an already 
open iridotomy as it is possible to damage the anterior lens capsule. 
Iridotomy should be of adequate size to remain patent life long. 
The indicators of complete patency is seeing the posterior pigment 
epithelium disrupted, watching for a through and through opening, an 
immediate flow of posterior chamber aqueous  humor through patent 
iridotomy  carrying pigments with it  into anterior chamber, visualization 
of anterior lens capsule and transillumination through the iridotomy 
accompanied by an immediate deepening of peripheral part of anterior 
chamber. 
If iridotomy is not complete with one application of laser beam, it 
is better to see another crypt. It is not usually wise to enlarge an 
iridotomy immediately as the edges are shredded and further applications 
may tend to sieve formation rather than an discrete iridotomy. It can be 
enlarged just to the side of previous iridotomy and even tiny Nd-YAG 
iridotomy remains patent. 
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Complication of Nd-YAG laser iridotomy: 
1) Iritis 
2) Pigment dispersion 
3) Haemorrhage 
4) Transient rise in IOP 
5) Lens opacities  
6) Rupture of anterior lens capsule 
7) Localized corneal odema or scar 
8) Failure to obtain patent iridotomy 
9) Late closure of iridotomy  
10)Transient pain and blurred vision.  
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MATERIALS AND METHOD  
This study includes two sets of patents. First group consists of  42 
eyes of 42  patients diagnosed as primary angle closure glaucoma, second  
one 40 eyes of 40 patients in which the other eye had history of PACG. 
Both group were treated with Neodymium-YAG laser iridotomies at the 
Department  of  Ophthalmology, Govt. Rajaji Hospital, Madurai between 
the period from April  2007 to August   2008. 
Selection criteria 
1) The patients who presented with acute angle closure glaucoma in 
one eye. 
2) The patients who had acute angle closure  glaucoma in one eye and 
were subjected to laser iridotomy as a preventive  measure for the 
fellow eye. 
Methods of examination: 
        All cases with any other ocular pathology were excluded from this 
study as well as secondary angle closure glaucoma cases were not taken 
up for this study. All the patients were evaluated with complete history, 
ocular examination with torch light , slit lamp biomicroscopy, visual 
acuity with Snellen’s E chart, intraocular pressure measurement with 
schiotz  indentation  tonometer. Anterior chamber depth examination with 
torch light, van Herick’s  slit lamp technique and goldmann 3 mirror 
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gonioscopy (Shaffer’s grading) and fundus examination were done in all 
cases. 
The provocative tests were not done. The patients with acute attack 
was treated with antiglaucoma  medications and Nd YAG laser iridotomy 
was only done when intra ocular pressure was under control and cornea 
had absolutely cleared. 
Patients were prepared for Nd YAG laser iridotomy with 2% 
pilocarpine and 4% xylocaine eye drops. Abraham contact lens was used 
in all cases. Iridotomy was done with coherent VISUALS YAG –II  laser 
made by m/s ZEISS, WEST GERMANY. Iridotomy was made either at 
11’ or 1’0  clock position in the peripheral iris. Either a crypt or thin area 
on the iris was selected. The amount of energy to make an opening on the 
iris was 4-6mJ.  
The iridotomy was considered patent when the posterior pigment 
epithelium was seen to be disrupted and a through and through opening 
was seen on the iris, An immediate flow of a posterior chamber aqueous 
humor gush through the patent iridotomy carrying pigments with it into 
the anterior chamber. Visualization of deepening of peripheral part of 
anterior chamber and transillumination were  conclusive evidences of the 
patency of the iridotomy. When the patency of iridotomy was doubtful 
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repeat Nd- YAG iridotomy was done either at the same spot or at a 
different site within a week. 
A follow up was conducted on these patients for a minimum period 
of  3 months. It included IOP measurement with Schiotz tonometer and 
goniscopy on the day of  iridotomy, after 1 hour, Second day, one week, 
one month and then three months after. Visual acuity recorded was 
checked in all cases post operatively and during follow up. 
All the patients were closely watched for intraoperative and post 
operative complications. Gonioscopy was  done to assess angle depth and 
to confirm the patency of  iridotomy in all patients. Post operatively all 
patients were put on cipro- dexamethasone 0.1% drop 4th hourly for a 
week. 
  Following Nd YAG laser iridotomy the patients with transient 
elevation in IOP of less than 10mm of Hg were treated with timolol 
maleate 0.5% twice daily and those with more than 10mm of Hg rise 
were given timolol maleate 0.5% twice daily along with tab. 
Acetazolamide 250mg thrice daily. 
The patients in whom peripheral anterior synechiae were involving 
more than 50% angle were not taken up for Nd YAG laser  iridotomy. In 
such cases a filtering surgery was done. 
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OBSERVATIONS & RESULTS 
1: AGE INCIDENCE: 
Total number of primary acute angle closure glaucoma patients 
who were treated with Nd YAG  laser iridotomy was 42.  These patients 
were grouped according to their age from below 40 years to 70 years with 
interval of 10 years. Maximum number of patients(50%) were between 
ages 51-60 years and minimum (4.76%)  patients were above 71 years. 
 
                                                     Table 1 
Age group No of patients Percentage 
40 - 50 years 5 11.90% 
51-60 21 50.00% 
61-70 14 33.30% 
71 and more 2 4.76% 
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2. Sex incidence 
A higher incidence was seen among females (66%)  than in males 
(33.33%) in this study. 
Table 2 
Percentage Total no of 
patients 
Males Females 
males females 
42 14 28 33% 66% 
 
3: Sex/age incidence 
Table 3 
                           Sex  
        age Males Females 
 
Percentage 
< 40 years Nil Nil nil 
41-50 Nil 5 12.00% 
51-60 7 14 50.00% 
61-70 6 8 33.33% 
71 and above 1 1 04.76% 
Total 14 28  
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4.  Distribution of patients according to age sex and diagnosis: 
Table 4 
Age group 30-40 41-50 51-60 61-70 >70 yrs 
Sex M F M F M F M F M F 
Acute PACG in 
one eye 
nil nil nil 5 7 14 6 8 1 1 
Treatment given as 
prophylaxis 
 nil nil nil 5 7 14 6 8 Nil Nil 
 
5. Energy requirements: 
Table 5 
Minimum total energy needed to obtain patent iridotomy was 46.42mJ 
Maximum total energy needed to obtain patent iridotomy was 117.50mJ 
Mean energy in males 52.80mJ 
Mean energy in females 60.79mJ 
Mean energy in light brown irides 95.90mJ 
Mean energy in brown irides 48.15mJ 
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6: Case wise distribution of bursts used & no of sitting done: 
Depending on the penetrability of the iris tissue, various bursts 
mode were used from one to five, maximum no. of cases were treated 
using three bursts (62% of cases). When the patency of the iridotomy was 
not attained with one sitting another attempt was made to perform to 
iridotomy within one week. 37 patients could be treated successfully in 
one sitting (88% of cases). Only 5 needed a repeat sitting within a period 
of one week (12% cases). 
                                                         Table 6 
1 burst Nil 
2 8 
No of bursts used 
3 32 
1st 37 No of sittings used 
2nd 5 
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7.  Table showing total energy, sittings required in both sex 
Table 7 
Males Females Total 
energy(mJ) 
<50 50-100 >100 <50 50-100 >100 
__ __ 1 __ __ 3 
2 5 __ __ 8 3 
2 4 __ __ 12 2 
Burst        1 
                 2 
                 3 
                 4 __ __ __ __ __ __ 
13 __ __ __ 24 __ Sittings    1 
                 2 1 __ __ __ 4 __ 
 
 
8.   Color of iris 
Table 8 
Brown color 42 cases 
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RESULTS 
• Primary angle closure glaucoma formed 0.74%. new cases in this 
hospital. 
• Female to male preponderance ratio is 2:1. 
• Peak presenting age of PACG was between 51-60 years , which 
formed 50%. 
• 42 eyes of 42 patients presenting with primary angle closure 
glaucoma were treated with Nd YAG laser iridotomy. In the same 
population 40 eyes of 40 patients with in the 42 patients were 
subjected to Nd YAG laser iridotomies on a prophylactic basis. 
• All eyes with acute stages of PACG had patent iridotomies at the 
3rd month of follow up. 
• 34  eyes which  were treated with Nd YAG laser iridotomy for 
PACG had angle closure attack for the first time and 8 eyes gave 
history suggestive of past attacks and synechiae less than 900. 
• No eyes with or without synechiae had shown closure of angle in 
the post YAG iridotomy period. 
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• In brown irides the minimal energy required to obtain patent 
iridotomy was 46.4mJ and maximum 100.5mJ. 
• In light brown irides the minimal energy required to obtain patent 
iridotomy was 90.6mJ and maximal was 120.8mJ. 
• The various complications recorded in this series of clinical study 
were the following. Pigment dispersion observed in 66.66% cases. 
Haemorrhage in the form of micro bleeding in 11% of cases and 
hyphema occurred in no cases. 66.66% eyes had recorded transient 
elevation of IOP and 12% had corneal oedema, of which 1 
cases(25%) developed multiple macular grade opacities in the 
follow up period. No other complications were recorded in the 
entire follow up of the series. 
• All the patients were given topical steroids in the post YAG period 
to control inflammation. 
• 25 patients who had post YAG increase in IOP of less than 10 mm 
of Hg were treated with timolol  maleate eye drops and 3 patients 
who had a raise of more than 10 mm of Hg were treated with 
timolol and oral acetazolamide. 
• All the cases included in the study showed permanent reduction in 
IOP, although 28 cases(66.66%) had shown a transient elevation of 
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IOP following the YAG  iridotomy. Maximum elevation was at the 
end of 1 hour procedure. These cases were responding very well to 
topical timolol and acetazolamide and IOP started lowering on 
second day. 
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Table 1 
Success rate of Nd YAG iridotomy in this study 
indication No of eyes 
treated 
% Patency after 
3 months 
closure Success 
rate 
Acute stage of 
PACG 
42 100% 42 nil 100% 
Prophylactically 
in the other eye 
40 100% 40 nil 100% 
 
Table 2 
Nd YAG iridotomy complications 
Complications No of eyes Percentage 
Pigment dispersion 28 66.66% 
Micro 
haemorrhage 
05 12% Bleeding  
Hyphema Nil 0.00% 
<10mm of Hg 25 60% Transient elevation 
of  IOP 
>10mm of Hg 3 7.00% 
Corneal oedema 4 12.00% 
Focal lens opacities Nil 0.00% 
Others Nil 0.00% 
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DISCUSSION 
In this study the effect of Neodymium YAG laser iridotomy was 
evaluated on 42 patients with acute angle closure glaucoma on a 
therapeutic and prophylactic basis. All the patients  were followed up for 
a period of 12wks during which the visual acuity, IOP and angle of 
anterior chamber were monitored. 
Of the 82 eyes studied there was a high correlation with the 
findings of Lowe R.F (30) and Hillman J S in 1979 (31). 
This study showed a female predilection of the disease which too is 
in good concurrence with the previous studies of Drance S.M (1973)32, 
Olurin O (1977) 33, Fontana S.T and Brubacker R.F (1980)34. 
The management of angle closure glaucoma has benefited 
considerably in the past decade by introduction of Argon laser iridotomy. 
In general laser iridotomy when compared to surgical iridectomy offers 
the advantage of less complications. Penetration of iris in blue and very 
dark brown irides present some difficulties with argon. Schwartz using 
pulsed argon laser reports 20% failure to penetrate brown iris and 35% 
failure to do so in blue iris. Post laser closure is another complication 
known to argon. Quigley reports that in 148 cases 50 cases had (33%) 
required retreatment. Pollack reports that in a series of 77 consecutive 
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cases which were followed up for 4 years 26 cases (34%) required 
retreatment. 
In contrast  to argon laser where action is thermal and causing 
effect by burning and shrinkage of iris tissue, the Nd YAG laser  for 
practical purposes is a cold laser, the tissue disruption being caused by 
optical breakdown and resulting shock waves. Transparent as well as 
pigmented tissue can therefore be cut with ease. Color of the iris becomes 
irrelevant . Nd YAG iridotomy appear to have minimal tendency to close 
in eyes uncomplicated by inflammation or neovascularization. 
Comparisons with the literature 
a. Efficacy and total energy required to obtain patent iridotomy. 
 Klapper R M  et al Naveh n et al Present study 
Single session 100% 90% 90.4% 
Two session Not available 10% 9.5% 
Total energy 32-96 mJ 20.8- 97 mJ 46.42 -117.5mJ 
 
b. Closure of Nd YAG laser iridotomy 
Pollack I P    
et al 
Klapper R M  
et  al 
Naveh N   
et al 
Present study 
Nil Nil 10% Nil 
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c.  Post Nd YAG iridotomy IOP  rise: 
It is now recognized as a common although usually transient 
complication. In present study 25 eyes showed an increase of less than 
10mm of Hg in IOP over the baseline. The greatest rise observed was at 1 
hour after YAG laser iridotomy. The maximum elevation in IOP was 
however 12.0mm of Hg. 
 
d.  Bleeding from iridotomy site: 
Moster M R Schwatrz 
spaeth G L et al 
Klapper R 
et al 
Naveh N et 
al 
Pollack I P 
et al 
Present 
study 
34.2% 15% 20% 45% 12% 
 
e) Corneal odema: 
Pollack I P   Robin A L Present study 
35% 12% 
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In this present study we were able to control the IOP below  23mm 
of Hg without any medication in 100% patients. 
Yamamoto J Shivato S 
Kitazawa Y 
 
Present study 
Without medication 29% 
With same or reduced medication 52% 
Increased medication 13% 
No control even with medication 6% 
 
Without medication 
100% 
 
The various complications reported by other authors like lens 
opacities, lens subluxation, monocular blurring, lens rupture and aqueous 
mis direction syndrome (malignant glaucoma) were not met in this study. 
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CONCLUSIONS 
  From the study we can conclude that primary angle closure 
glaucoma, is an uncommon disease of the sixth decade,. It must be 
diagnosed and managed quickly and effectively to prevent visual loss. 
Once an acute attack has been controlled with anti glaucoma 
medication, a Nd YAG laser iridotomy is indicated and it can be safely 
and successfully done to prevent the attack from recurring. It has also 
been found to be of much safety and efficacy in the fellow eyes of 
patients in whom one eye suffered an attack or gives a past history 
suggestive of it. 
Nd  YAG laser iridotomy is indicated in the prodromal stage, stage 
of constant instability and acute congestive stage. 
A laser setting of multiple bursts with low total energy has been 
found to be more effective than burst with high total energy. 
Transient elevation in IOP, micro haemorrhage, pigment 
dispersion, corneal odema and delayed opacification were seen as the 
most frequent complications. The transient elevation in IOP was seen for 
a period of 1-3 hours, the peak of which was seen in 1 hour and it could 
be controlled with topical B- blocker agent alone or in combination with 
acetazolamide. The bleeding was from the iris vessels and was in the 
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form of micro haemorrhage. No case of hyphema was seen. Corneal 
oedema which occurred in very few cases in the immediate post laser 
period was self limiting and fully resolved in all cases within a period of 
1 week. 
The other complication of Nd YAG laser iridotomy reported by 
previous studies like lens opacification, subluxation, aqueous 
misdirection syndrome were not reported in this study. 
All the patients treated showed considerable reduction in IOP 
increase in the angle of the anterior chamber and significant improvement 
in visual acuity. 
Anti-glaucoma medications could be stopped as soon as the IOP 
started lowering following  a functioning laser iridotomy and all the 
patients were well stabilized at the end of the follow up. 
Prophylactic iridotomy in the other eyes efficiently prevented an 
attack of angle closure glaucoma. 
It follows that Nd YAG laser iridotomy is particularly beneficial to 
reduce the IOP in primary angle closure glaucoma and is a very efficient 
measure in preventing an attack of angle glaucoma in predisposed eyes. 
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PROFORMA 
A. Name of the patient:                                           Hospital No.  
Age:                                sex:      
B. History of present illness: pain/colored haloes/ blurred vision 
                                               headache/ redness 
Treatment history: 
Optical history: 
Family history: 
C. Examination findings                                    RE                         LE 
congestion     conjunctival 
                         ciliary 
cornea           clear/ hazy 
                        epithelium 
                        stroma 
                       endothelium  
anterior chamber      general depth  
                                  shallow/ normal 
                                  peripheral depth   grade 4/3/2/1 
                         (using slit lamp technique of van herick) 
A C content: clear/ flare/ flare & cells/pigments. 
iris bombe :           yes/    no 
iris               color: dark brown/medium brown/ blue 
                     pattern: normal/ distorted 
                     atrophy: yes/ no  
pupil :   size: normal / dilated 
               shape: round / vertically oval/ irregular 
              reaction: brisk/ sluggish/ non reacting 
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synechiae:           yes /     No 
lens :                  clear/ pigments over anterior capsule 
visual acuity: snellen’s test types. 
fundus:  direct ophthalmoscope: 
                    disc: 
                    vessels: 
                     macular 
                    back ground: 
I.O.P: schiotz tonometry: 
goniscopy: goldmann’s triple mirror lens :  grade 4/3/2/1/0. 
( shaffer’s system of grading angle) 
D. Laser iridotomy indications: prodromal/ constant instability / acute 
congestive / fellow eye with ACG. 
E. Pre Nd-YAG( if any): 
pilocarpine/ timolol maleate/ acetazolamide/ mannitol. 
Duration 
F. Status after pre Nd-YAG treatment: I.O.P   
G. Details of Nd -YAG iridotomy: 
topical anaesthesia  :  yes / no 
iridotomy site   :  upper temporal / upper nasal 
energy setting  :  ……..mJ. 
No.of shots    : 
No. of setting required to attain patency : one / two/more than two. 
H. Follow up:  :  post  YAG  I.O.P    vision     AC depth     gonioscopy 
a) after 1 hour 
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    b) after 2 hour  
    c) after 1 day 
    d) after 1st week 
    e) after 1 month 
     f) after 3 months 
I. Post Nd YAG iridotomy treatment (if any) 
corticosteroids/ pilocarpine/ timolol maleate/ acetazolamide 
duration 
J. Complications following Nd YAG laser iridotomy. 
a) Transient pain & blurred vision  
b) Corneal  burns / endothelial loss 
c) Iris pigment release / bleeding from iridotomy site/ micro 
haemmorrhage/ hyphaema.  
d) Uveitis 
e) Lens : perforation of lens capsule  Localized non progressive lens 
opacity. 
f) Retina : retinal burns/ CME/ retinal detachment. 
g) IOP rise: transient / prolonged. 
h) Visual loss: 
i) Choroidal detachment 
j) Failure to obtain patent iridotomy 
k) Late closure of iridotomy. 
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Appendix-I 
Abbreviations used: 
AACG -  acute angle  closure glaucoma. 
AG  - absolute glaucoma 
ACD  -  anterior chamber depth 
AZ  - acetazolamide 
BV  -  blurring of vision 
Ch  -  colored halos 
CF  -  counting fingers 
CCC  -  circum corneal congestion 
CE  -  corneal odema 
CO  -  corneal opacity 
CG  -  chronic glaucoma 
Gn  - gonioscopy 
HE  -  micro haemorrhage 
Gr  - grade 
HA  -  headache 
IOP  - intra ocular pressure 
LE  -  left eye 
µM  - microns 
 70
mJ  - milli Joules 
mm  - millimeter 
Pa  - pain 
PAS  -  peripheral anterior synechae 
PACG -  primary angle closure glaucoma 
PL  -  perception of light 
PD  -  pigment dispersion 
PG  -  prodromal stage 
PI  - peripheral Iridotomy 
PY-I  -  prophylactic iridotomy 
RE  -  right eye  
R   - redness 
S   - steroid  
Sy  - symptoms 
Sn  -  Signs. 
T  -  timolol maleate 
VA  -  Visual acuity 
Tr.ill  -  trans illumination 
+ve  -  patent iridotomy 
-ve   - closed iridotomy. 
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Appendix II 
Master chart—1 
Details of clinical presentation of PACG 
Sl 
No 
Name Hospital
No 
Age 
Sex 
Eye
Rx 
Clinical 
features 
Signs & 
ACD 
Gn 
gr 
IOP 
mm 
of Hg 
V .A 
1 Muthukarupan  78216 73M RE Pa, Bv CE+III 0 44.5 6/24 
2 Govindarajan  78538 52M LE Bv,PA+ CE+II 0 54.2 6/12 
3 Chinnamma  75004 71  F RE Bv+Pa+ CE+ I 0 64.0 6/24 
4 Ponthayee  75095 43 F RE Bv+ Pa+ II 0 59.1 6/12 
5 Manikandan  75118 56M LE Pa+ I 0 18.9 6/24 
6 Muniyammal  75293 48 F RE Bv+ CE+ 0 42.14 6/36 
7 Thangamani 75707 63M  RE Pa+ Bv+ CCC ,I 0 49.8 6/9 
8 Palanimmal  76097 60F LE Bv+ I 0 53.6 6/60 
9 Periyadakki  78353 45F LE Pa+,Ch+ II CCC+ 0 43.4 6/18 
10 Pushpam  80818 57F LE Ch+ I 0 40.2 6/12 
11 Periyadakkan 81864 69M LE Pa+ I 0 81.7 PL 
12 Mariappan  84225 59M RE Bv+ CE+ I 0 49.8 6/12 
13 Karupaiah  85005 52M LE Bv+ CE+ II 0 57.6 6/24 
14 Janaki  85234 62 F LE Pa+ Bv+ II 0 49.9 6/18 
15 Subbammal  89543 59 F LE Bv+ CCC+ II 0 40.2 6/18 
16 Gopalakrishna 91003 48M LE Pa+ Ch HA CE+ I 0 53.6 6/36 
17 Tamilselvam 92340 58M LE Ch+ CE+ I 0 50.6 6/36 
18 Thayammal  960831 53 F LE Ch+ Bv+ CE+I 
CCC+ 
0 34.5 6/18 
19 Vasantha  96566 65 F RE Bv+Ch+HA
+ 
CE+ I 0 41.5 6/12 
20 Pandiammal  97456 61 F RE Pa+ CCC+ 
CE+ 
0 38.8 6/12 
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Sl 
No 
Name Hospital
No 
Age 
Sex 
Eye
Rx 
Clinical 
features 
Signs & 
ACD 
Gn 
gr 
IOP 
mm 
of Hg 
V .A 
21 Vellaiammal  98269 52 F RE Pa+ Bv+ CCC= 0 64.0 6/24 
22 Seethammal  98510 52 F RE Bv+ CE+II 0 66.2 6/24 
23 Adakki  98892 54 F RE Bv+ CE+ I 0 35.8 6/36 
24 Pandi  99102 63 M RE Bv+ Ch+ CCC+ I 0 54.2 6/24 
25 Muniyandi  99456 70 M LE Bv+Ch+ CCC+ 0 41.5 6/367 
26 Kadeeja begaum 99503 58 F LE Ch+ HA+ CCC+ II 0 37.8 6/60 
27 Ponnamma  100558 60 F LE Bv+ CCC+ 
CE+ 
0 45.8 6/60 
28 Lakshmi  102459 61 F LE Bv+ CE+ II 0 46.9 6/36 
29 Periyalagan  103700 68 M LE Bv+ CE+ II 0 37.8 6/24 
30 Chinakarupaiah 103457 58 M RE *Ch+ CE+I 0  59.8 5/60 
31 Jeyasheela  105780 63 F RE Pa+ CE+ 0 54.2 CF3m
32 Shanmugam  104560 52 M LE Pa+ Bv+ CE+ I 0 46.9 6/60 
33 Muthupandian 110980 54 M LE Ch+ HA+ CE+ I 0 64.0 6/36 
34 Haneefa begaum  113806 56 F RE Ch+ Bv+ CE+II 0 34.5 6/24 
35 Eshwari  116890 55 F LE Bv+ CCC+II 0 57.6 6/60 
36 Mariammal  118456 62 F RE Bv+ Pa+ CE+ I 0 49.9 6/36 
37 Ramuthayee  119034 63 F LE Ch+ CE+ I 0 43.4 6/24 
38 Alagammal  123209 63 F RE Pa+Ch+HA
+ 
CE+II 0 53.6 6/60 
39 Chinnadaki  126703 60 F LE Pa+ CE+ I 0 42.1 6/36 
40 Saithanbeevi  129043 53 F RE Bv+ CE+II 0 59.1 6/36 
41 Meenammal  157803 64 F LE Bv+ CE+CC
C+ 
0 54.7 6/60 
42 Palaniammal  160234 54 F LE Bv+ CE+ I 0 50.6 4/60 
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Master chart -2 
Treatment data 
Sl 
no 
IOP pre 
YAG 
Total 
energy 
Post YAG Rx 
features 
Post YAG 
VA 
Poat YAG Gn,    
Trans illumination 
1 26.6 84.4 S 6/24 III Tr+ 
2 24.4 96.0 S+T 6/12 F III Tr+ 
3 29.0 78.5 S+ T 6/24 III Tr+ 
4 22.4 87.6 S+ T 6/18P III Tr+ 
5 20.6 89.0 S 6/24 III Tr+ 
6 23.8 74.0 S 6/36 II Tr+ 
7 23.1 96.0 S+T 6/18 III Tr+ 
8 22.4 108.0 S+T+Az 6/60 III Tr+ 
9 26.6 92.0 S+T 6/18 II Tr+ 
10 23.1 96.0 S+T 6/12 III Tr+ 
11 33.0 72.0 S 6/18 III Tr+ 
12 25.1 98 S 6/12 III Tr+ 
13 24.4 46.8 S 6/18 III Tr+ 
14 20,6 70 S+ T 6/9 III Tr+ 
15 23.8 92.5 S+T 6/18 III Tr+ 
16 25.8 94.5 S+ 6/24 II Tr+ 
17 20.6 48.4 S 6/36 III Tr+ 
18 23.8 51.9 S+T 6/18 II Tr+ 
19 24.4 60.4 S+T 6/12 III Tr+ 
20 20.6 90.6 S+T 6/24 III Tr+ 
21 25.8 72 S+T 6/24 II Tr+ 
22 29.0 42.6 S 6/24 III Tr+ 
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Sl 
no 
IOP pre 
YAG 
Total 
energy 
Post YAG Rx 
features 
Post YAG 
VA 
Poat YAG Gn,    
Trans illumination 
23 23.8 54.8 S 6/36 II Tr+ 
24 30.4 24.1 S+T+Az 6/60 II Tr+ 
25 24.4 69.8 S+T 6/24 III Tr+ 
26 22.4 77.0 S+T 6/60 III Tr+ 
27 29.0 98.0 S+T 6/60 III Tr+ 
28 22.4 76.4 S+T 6/36 III Tr+ 
29 23.0 68.4 S+T 6/24 III Tr+ 
30 23.1 102 S+T+Az 6/36 II Tr+ 
31 26.6 99 S+T 6/24 III Tr+ 
32 23.8 100.5 S+T 6/60 III Tr+ 
33 21.3 99 S+T 6/36 III Tr+ 
34 29.0 120.8 S+T 6/24 II Tr+ 
35 26.6 90.6 S+T 6/24 II Tr+ 
36 23.1 56.4 S 6/18 III Tr+ 
37 25.8 36.4 S 6/24 III Tr+ 
38 23.8 75.0 S+T 6/18 III Tr+ 
39 22.4 71.8 S+T 6/24 III Tr+ 
40 20.6 79.5 S+T 6/36 II Tr+ 
41 18.5 46.6 S 6/12 III Tr+ 
42 28.0 102.5 S+T 6/60 II Tr+ 
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Master chart 3 
Follow up data IOP, Gn,VA 
Sl 
No 
1st hour 2nd day 1st week 1st month 3rd month Compli 
cations 
1 24.4,III,6/18 23.8III 6/18 23.8 III 6/12 21.3 III 6/12 19.6 6/12 PD,  
2 31.6 III 6/12 28.3III 6/12 23.8III 6/12 20.6 III 6/9 20.6/9 MHE 
3 20.6III 6/24 19.6III 6/12 21.3 III 6/24 18.9III 6/24 18.9 6/24 PD 
4 34.5III 6/24 33.0III,6/24 23.8 III6/24 20.6III 6/24 20.6 6/24 NIL 
5 19.6 III 6/12 19.6III 6/12 18.9 III6/12 18.9 III 6/12 18.9.6/9 PD  
6 22.4 III 6/36 21.9III 6/36 19.3III6/18 18.9 III 6/12 18.9 6/12 NIL 
7 28.0 III 6/9 26.6 III 6/9 23.1 III 6/9 21.9 III 6/9 20.6 6/6P NIL 
8 34.4 III 4/60 31.8II 4/60 30.4III 6/24 23.8III 6/18 21.6 6/18 PD CE 
9 31.8II 6/18 23.1 II 6/18 23.1 II6/12 20.6 II 6/12 18.9 6/9P NIL 
10 17.3II 6/12 17.0 II 6/12 17.3 II 6/12 17.3 II 6/12 17.3 6/12 NIL 
11 17.3 II 6/24 15.8II 6/18 14.6II 6/18 14.6 II 6/12 15.96/12 NIL 
12 29.4II 6/24 35.8 III6/24 31.8III6/12 23.1III 6/12 20.6,6/12 PD MHE 
13 23.8 II 6/24 21.3II6/24 21.3 II 6/24 21.3 III 6/24 20.6 6/24 MHE 
14 29.0III6/12 21.9III6/12 18.9 III 6/9 17.3III 6/9 17.3 6/9 NIL 
15 23.8II 6/18 20.6II6/18 20.9 II 6/18 18.9II6/9 17.3 6/12 NIL 
16 31.8II 5/60 27.2II6/60 21.9II 6/24 19.8 III6/18 18.9 6/18 MHE .CO 
17 33.9II 6/36 27.2II6/36 21.9II6/18 20.6III6/18 20.6 6/18 NIL 
18 28.0III6/18 21.3III6/18 20.6III 6/18 18.9III 6/18 18.9 6/12P NIL 
19 29.4III6/18 23.8III6/18 21.8III6/12 21.9III 6/12 19.8 6/12 NIL 
20 29.3III 6/24 3.8III6/24 20.6III6/18 18.9II 6/18 20.6  6/18 NIL 
21 28.6 III 6/24 20.6III6/24 20.6 III6/12 18.9III 6/12 18.9 6/9 NIL 
22 20.1III6/24 18.9II6/24 17.3III6/12 17.3III6/12 17.3 6/9P NIL 
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Sl 
No 
1st hour 2nd day 1st week 1st month 3rd month Compli 
cations 
23 31.6II6/36 24.4II 6/36 21.3 II 6/18 20.6 II 6/12 MHE 
24 28 II 6/18 20.6II6/18 19.8II 6/12 18.9II6/12 17.3 6/12 NIL 
25 27.2III6/36 22.4III6/36 22.4III6/12 20.6III6/12 20.66/12 NIL 
26 26.6III6/60 18.9III6/60 18.9III6/24 17.3III6/18 18.9 6/12 NIL 
27 18.5III6/60 18.5III6/60 17.3III6/24 17.3III6/12 17.3 6/9 NIL 
28 26.6III 6/36 21.9III6/36 20.6III6/24 20.6III6/12 20.6 6/12 PD 
29 27.2III6/24 23.1III6/24 21.3III 6/12 21.3III6/12 20.6 6/12 NIL 
30 29.0III6/24 21.3III6/60 21.3III 6/60 21.3III6/18 20.6 6/12 NIL 
31 30.4IIICF 25.8 III CF 21.3III6/36 21.3 III 6/18 20.6 6/18 MHE 
32 21.3III6/60 18.9III6/60 15.9III6/24 15.9III6/24 17.3 6/12 NIL 
33 26.6II6/24 18.9II6/24 18.9II6/18 18.9 II 6/12 18.9 6/9P NIL 
34 33 II 6/60 28II 6/60  23.8II 6/24 23.8II6/12 20.6 6/9 CE CO 
35 29.4II 6/24 23.8II6/24 21.3II6/24 21.3II6/9 20.6 6/9 MHE 
36 21.3III6/60 18.9III6/60 18.9III6/18 18.9III6/9 18.9 6/9 NIL 
37 29.0III6/18 22.4III6/18 22.4III6/18 22.4III6/12 20.6 6/12 PD 
38 26.6 III 6/24 23.8 III6/24 20.6 III6/9 20.6III6/9 20.6 6/9 NIL 
39 28.0II6/60 21.8II6/60 20.6II6/12 20.6II6/12 20.6 6/12  CE 
40 24.4II 6/12 20.6II6/12 20.6II6/12  20.6 II 6/12 20.6 6/6P NIL 
41 17.3 III6/12 15.9III6/12 15.9III6/12 15.9III6/6P 15.9 6/6P NIL 
42 31.8II6/60 24.4II6/60 24.4II 6/24 120.6II 6/24 20.6 6/12 NIL 
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Master chart 4 
Details of cases in which fellow eye was treated prophylactically. 
 
Sl no Name Hosp. 
no 
age Eye 
treated 
IOPmm 
of Hg 
Gn VA Post 
YAG 
IOP mm 
of Hg 
Post 
YAG 
VA 
1 Govindarajan  78538 52M RE 21 I 6/9 19.6 6/9 
2 Ponthayee  75095 43 F LE 18.4 II 6/18 15.9 6/12 
3 Manikandan  75118 56M RE 17.3 II 6/12 17.3 6/9P 
4 Muniyammal  75293 48 F LE 17.3 I 6/24 17.3 6/18 
5 Thangamani 75707 63M  LE 17.3 II 6/12P 17.3 6/12 
6 Palanimmal  76097 60F RE 18.9 I 6/12 17.3 6/9 
7 Periyadakki  78353 45F RE 21 I 6/24 17.3 6/18 
8 Pushpam  80818 57F RE 20.6 II 6/6 18.4 6/6 
9 Periyadakkan 81864 69M RE 17.3 II 6/6P 17.3 6/6 
10 Mariappan  84225 59M LE 18.9 I 6/12 15.9 6/12 
11 Karupaiah  85005 52M LE 18.9 I 6/9 15.9 6/9 
12 Janaki  85234 62 F RE 17.3 I 6/9 14.6 6/6 
13 Subbammal  89543 59 F RE 19.6 I 6/24 17.3 6/24 
14 Gopalakrishna 91003 48M RE 15.9 II 6/6 14.6 6/6 
15 Tamilselvam 92340 58M RE 16.2 II 6/9 15.9 6/9 
16 Thayammal  960831 53 F RE 18.6 II 6/6 17.3 6/6 
17 Vasantha  96566 65 F LE 17.3 II 6/24 17.3 6/12 
18 Pandiammal  97456 61 F LE 20.6 II 6/24 18.9 6/24 
19 Vellaiammal  98269 52 F LE 18.9 II 6/36 18.9 6/36 
20 Seethammal  98510 52 F LE 17.3 II 6/18 17.3 6/18 
21 Adakki  98892 54 F LE 14.6 II 6/24 14.6 6/24 
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S.No. Name Hospital 
No 
Age 
Sex 
Eye 
Rx 
IOPmm 
of Hg 
Gn VA Post 
YAG 
IOP mm 
of Hg 
Post 
YAG 
VA 
22 Pandi  99102 63 M  LE 17.3 I 6/24 17.3 6/24 
23 Muniyandi  99456 70 M RE 18.9 I 6/36 18.9 6/36 
24 Kadeeja begaum 99503 58 F RE 14.6 II 6/60 14.6 6/60 
25 Ponnamma  100558 60 F RE 17.3 II 6/60 17.3 6/60 
26 Lakshmi  102459 61 F RE 18.9 II 6/24 18.9 6/24 
27 Periyalagan  103700 68 M RE 18.9 II 6/24 18.9 6/24 
28 Chinakarupaiah 103457 58 M LE 17.3 II 6/36 17.3 6/36 
29 Jeyasheela  105780 63 F LE 18.9 II 6/60 18.9 6/60 
30 Shanmugam  104560 52 M RE 17.3 II 6/36 17.3 6/36 
31 Muthupandian 110980 54 M RE 14.6 II 6/24 14.6 6/24 
32 Haneefa begaum  113806 56 F LE 17.3 II 6/24 17.3 6/24 
33 Eshwari  116890 55 F RE 15.9 II 6/24 15.9 6/24 
34 Mariammal  118456 62 F LE 18.9 II 6/18 18.9 6/18 
35 Ramuthayee  119034 63 F RE 20.6 II 6/24 20.6 6/24 
36 Alagammal  123209 63 F LE 18.9 I 6/36 18.9 6/36 
37 Chinnadaki  126703 60 F RE 15.7 II 6/36 15.7 6/36 
38 Saithanbeevi  129043 53 F LE 17.3 II 6/36 17.3 6/36 
39 Meenammal  157803 64 F RE 17.3 II 6/36 17.3 6/36 
40 Palaniammal  160234 54 F RE 18.9 II 6/60 18.9 6/60 
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PERIPHERAL LASER IRIDOTOMY RELIEVING  
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